IRAK1/4 and BET bromodomain inhibitions converge in NF-κB blockade and offer synergistic antitumoral activity in ABC-DLBCL with MYD88 mutation
- Resource Type
- Abstract
- Source
- In
Clinical Lymphoma Myeloma and Leukemia September 2015 15 Supplement 2:S64-S65 - Subject
- Language
- ISSN
- 2152-2650